Biocon Sdn Bhd’s insulin glargine drug substance, drug product, and device assembly facilities in Malaysia underwent a pre-approval inspection by the USFDA between June 24 and July 5, 2019, Biocon said in a filing to BSE.
USFDA issues 12 observations for 3 Biocon units in Malaysia
More from Industry NewsMore posts in Industry News »
- Frontline, medical workers need to take booster shots, say experts
- India tells Quad will allow export of 8 mln Indo-Pacific vaccine doses
- We need to be vigilant towards counterfeit products: Nakul Pasricha,President, ASPA
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference